Utility Menu French

National Association of Pharmacy Regulatory Authorities

Provinces French

Main navigation French


Recherchez dans la Base de données des annexes nationales de médicaments

Commencez votre recherche en utilisant le nom générique du produit :

Recherche par annexe
Réinitialiser

ATTENTION : Tous les résultats de la recherche seront tirés du « National Drug Schedules » du site Web en anglais.

Nom du médicament (en anglais) Commentaire Annexe Date
Obeticholic acid or its saltsPDL I MAY / 17
ObinutuzumabPDL I DEC / 14
Oclacitinib or its saltsPDL

including but not limited to Oclacitinib maleate

I AUG / 14
OcrelizumabPDL I SEP / 17
Octatropine methylbromideF1 I SEP / 98
OctreotideF1 I SEP / 98
Ofloxacin and its saltsF1 I SEP / 98
Olanzapine and its saltsF1 I SEP / 99
OlaparibPDL I AUG / 16
Oleandomycin and its salts and derivativesF2 I SEP / 98
Olmesartan and its salts and derivativesF1 I MAR / 11
Olopatadine and its saltsF1 I SEP / 98
Olsalazine and its saltsF1 I SEP / 98
OmalizumabF1 I FEB / 07
OmbitasvirPDL I MAR / 15
Omeprazole or its saltsPDL

including but not limited to omeprazole, omeprazole magnesium except when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of omeprazole

I SEP / 14
Omeprazole or its salts.

when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of omeprazole

II SEP / 14
Ondansetron and its saltsF1 I SEP / 98
OpiumN I JUN / 02
Orbifloxacin and its salts and derivativesF1 I MAY / 04
OrciprenalineF1 Metaproterenol and its salts I SEP / 98
Ormetoprim and its saltsF1 I SEP / 98
OrnidazoleF1 I SEP / 98
Orphenadrine citrate III SEP / 98
Orphenadrine hydrochloride I SEP / 98
Oseltamivir and its saltsF1 I MAR / 01
Osimertinib or its saltsPDL I AUG / 16
Oxabolone and its derivativesC3 I SEP / 98
OxaliplatinF1 I SEP / 08
OxanamideF1 I SEP / 98
OxandroloneC3 I JUN / 02
Oxaprozin and its salts and derivativesF1 I SEP / 98
Oxazepam and its saltsTS I SEP / 98
OxazolamTS I JUN / 02
OxcarbazepineF1 I DEC / 01
Oxethazine III SEP / 98
Oxiconazole 1% for topical use U SEP / 99
Oxolinic acid and its saltsF1 I SEP / 98
Oxprenolol and its saltsF1 I SEP / 98
Oxybuprocaine and its salts benoxinate for opthalmic or parenteral use II SEP / 98
Oxybuprocaine and its salts for topical use on mucous membranes, except lozenges III SEP / 98
Oxybutynin and its saltsF1 I SEP / 98
OxycodoneN I JUN / 02
OxymesteroneC3 I JUN / 02
Oxymetazoline in nasal preparations for adult use and in ophthalmic products U
Oxymetazoline and its salts in nasal preparations for pediatric use II SEP / 98
OxymetholoneC3 I JUN / 02
OxymorphoneN I JUN / 02
Oxyphenbutazone and its saltsF1 I SEP / 98
Oxyquinoline II SEP / 98
OxytocinF1 I SEP / 98
Ozenoxacin or its saltsPDL I JUN / 17

52 résultats


Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations}
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drus Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled